 Drug Synergism
"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 6 | 6 | | 1996 | 0 | 6 | 6 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 4 | 4 | | 2001 | 0 | 7 | 7 | | 2002 | 0 | 9 | 9 | | 2003 | 0 | 9 | 9 | | 2004 | 0 | 10 | 10 | | 2005 | 0 | 9 | 9 | | 2006 | 1 | 8 | 9 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 14 | 14 | | 2009 | 0 | 9 | 9 | | 2010 | 0 | 8 | 8 | | 2011 | 0 | 13 | 13 | | 2012 | 0 | 7 | 7 | | 2013 | 0 | 9 | 9 | | 2014 | 2 | 9 | 11 | | 2015 | 0 | 10 | 10 | | 2016 | 1 | 8 | 9 | | 2017 | 0 | 12 | 12 | | 2018 | 0 | 7 | 7 | | 2019 | 0 | 2 | 2 | | 2020 | 0 | 6 | 6 | | 2021 | 0 | 6 | 6 | | 2024 | 2 | 4 | 6 | | 2025 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
-
Thacker JS, Ralph LT, Koek L, Abbasian A, Bettio LB, Smith AE, Georgiou J, Christie BR, Collingridge GL. Synergistic actions of corticosterone and BDNF on rat hippocampal LTP. Mol Brain. 2025 May 12; 18(1):42.
-
Kaplan JB, Muzaleva A, Sailer M, Huizinga RB, Kridin K. Synergistic activity of dispersin B and benzoyl peroxide against Cutibacterium acnes/Staphylococcus epidermidis dual-species biofilms. PLoS One. 2025; 20(3):e0320662.
-
Esquer H, Zhou Q, LaBarbera DV. Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer. Cells. 2025 02 20; 14(5).
-
Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, Zhou Q, Messersmith WA, LaBarbera DV. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. Int J Mol Sci. 2024 Dec 07; 25(23).
-
Li L, Hashemi L, Eid J, Tao W, Campoverde L, Yu A, Farooqi AA, Al-Ali H, D'Amato G, Hornicek F, Duan Z, Lohse I, Trent J. High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation. Int J Mol Sci. 2024 Dec 03; 25(23).
-
Wu A, Yan J, Su T, Feng C, Long X, Pan Y, Ye R, Xia T, Long H, Wu J, Xiao X. Trametinib boosts palbociclib's efficacy in breast cancer via autophagy inhibition. Oncol Res. 2024; 32(7):1197-1207.
-
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Sci Rep. 2024 05 17; 14(1):11325.
-
Dousa KM, Shin E, Kurz SG, Plummer M, Nantongo M, Bethel CR, Taracila MA, Nguyen DC, Kreiswith BN, Daley CL, Remy KE, Holland SM, Bonomo RA. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024 Jun 12; 15(6):e0060924.
-
Pandey K, Acharya A, Pal D, Jain P, Singh K, Durden DL, Kutateladze TG, Deshpande AJ, Byrareddy SN. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2. Antiviral Res. 2024 07; 227:105904.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|